Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CA-4948 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation (CA4948 + FOLFOX + Nivolumab) | EXPERIMENTAL | * CA4948 (dose will depend on dose level assigned) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days. * Each cycle is 14 days. |
| Dose Expansion Cohort A (CA4948 + FOLFOX + Nivolumab) | EXPERIMENTAL | * CA4948 (dose will be the recommended phase II dose found in the dose escalation portion of study) twice daily by mouth. Standard of care mFOLFOX7 every 14 days. Nivolumab every 14 days. * Each cycle is 14 days. |
| Dose Expansion Cohort B (CA4948 + FOLFOX + Pembrolizumab + Trastuzumab) | EXPERIMENTAL | * CA4948 (dose will be the recommended dose found in the dose escalation portion of study) twice daily by mouth Standard of care mFOLFOX7 every 14 days. Pembrolizumab on day 1 of every 3 cycles. Trastuzumab every 14 days. * Each cycle is 14 days. |
| Name | Type | Description |
|---|---|---|
| CA-4948 | DRUG | Provided by Curis, Inc. |
| Nivolumab | BIOLOGICAL | 240 mg IV on Day 1 of each cycle |
| Pembrolizumab | BIOLOGICAL | 400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years |
| Trastuzumab | DRUG | 6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle |
| mFOLFOX7 | DRUG | Standard of care |
Inclusion Criteria: * Advanced unresectable or metastatic histologically or cytologically confirmed adenocarcinoma or squamous cell carcinoma of the stomach, gastroesophageal junction, or esophagus * Measurable or evaluable disease defined by RECIST 1.1. * Lesions amenable to research biopsy. This ...
Top 20 of 45 competitors
CA-4948 is an investigational small molecule being studied for the treatment of gastric cancer, specifically in combination with FOLFOX and a PD-1 inhibitor, with or without trastuzumab, for untreated unresectable gastric and esophageal cancer. It is currently in Phase 1 clinical development.
CA-4948 targets IRAK4, a kinase enzyme involved in inflammatory signaling pathways. By inhibiting IRAK4, CA-4948 may interfere with tumor-promoting signals in cancer cells. This mechanism is being explored in the context of gastric and esophageal cancers.
CA-4948 is being developed by Curis, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CRIS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in oncology.
CA-4948 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in combination therapies for gastric and esophageal cancers.
CA-4948 is being studied in a Phase 1 clinical trial with the identifier NCT05187182. This trial is evaluating CA-4948 in combination with FOLFOX and a PD-1 inhibitor, with or without trastuzumab, in patients with untreated unresectable gastric and esophageal cancer. The trial is recruiting in the United States and aims to enroll 42 participants.
No, CA-4948 is not the same as emavusertib. CA-4948 is a distinct investigational small molecule targeting IRAK4, developed by Curis, Inc. It is being studied for gastric and esophageal cancers. Emavusertib is a different drug with its own development program and target.